FINWIRES · TerminalLIVE
FINWIRES

Update: Keyera's Purchase of Plains All American's Natural Gas Liquids Assets Challenged by the Competition Bureau

By

-- (Adds comments from Keyera in paragraphs five and six; updates shares.)

Keyera (KEY.TO) faces official pushback on its $5.15-billion acquisition of Plains All American Pipeline's (PAA) Canadian natural gas liquids assets as the Competition Bureau on Tuesday said it filed an application with the Competition Tribunal challenging the deal.

The bureau said in a release it believes "the proposed transaction is likely to harm competition in natural gas liquids processing and storage, particularly at Fort Saskatchewan, Alberta, Canada's primary hub for these services".

The bureau said the referral to the Tribunal follows on an investigation that concluded the acquisition would eliminate a close competitor in the Fort Saskatchewan market and increase market concentration. It also said the merged company would have the "ability to increase prices, impose less favourable contract terms, reduce incentives to expand capacity, and further entrench control over critical infrastructure".

When it first announced the acquisition in July of last year, Keyera said the purchase would add natural-gas liquids fractionation and processing facilities, as well as 23-million barrel of oil storage, 1,500 miles of pipelines and terminal infrastructure in Western Canada and Ontario.

In a statement, Keyera said it received a filing from the Competition Bureau shortly before markets opened on Tuesday It said the bureau's challenge does not prevent it from closing the acquisition and disagreed with the claims.

"The Company disagrees with the Commissioner's assertions and characterization of the Transaction, and intends to respond to the application. As the Company has previously advised, the Transaction will strengthen competition across the basin and provide customers with improved access to key markets and greater flexibility in how their products are handled, transported and sold," it said.

Keyera shares were last seen down $2.17 to $50.80 on the Toronto Stock Exchange.

Price: $50.76, Change: $-2.21, Percent Change: -4.17%

Related Articles

Australia

American Electric Power CEO Says Speed to Market Key Issue in Load Connection

American Electric Power (AEP) CEO Bill Fehrman said Tuesday that speed to market is the main issue in efficiently connecting energy load to generation.In a Q1 earnings call, Fehrman said that, in particular, the performance and stakeholder approval process of PJM, the US mid-Atlantic grid operator, represents a major challenge."The current state of PJM's performance and stakeholder approval process does not give me great confidence that these issues will be resolved any time soon," Fehrman said on the call."In fact, if something is not done now, I expect we could still be having these same conversations in 10 years," he added.Expanding and strengthening the grid will ensure new generation resources can connect quickly, reliably, and affordably to serve the growing load, the CEO said.Price: $137.27, Change: $+2.61, Percent Change: +1.94%

$AEP
Australia

MGE Energy Q1 Earnings, Revenue Rise

MGE Energy (MGEE) reported Q1 earnings Tuesday of $1.32 per diluted share, up from $1.14 a year earlier.One analyst polled by FactSet expected $1.13.Revenue for the three months ended March 31 was $242.7 million, up from $219 million a year earlier.Price: $80.48, Change: $+0.36, Percent Change: +0.46%

$MGEE
Research

Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.

$PFE